---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-011645"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2024-04-10T23:59:59+00:00"
generated_at: "2026-06-04T00:19:13.635708+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# DiaMedica Therapeutics SVP Julie VanOrsdel Daves resigns; Rebekah de Vitry Fries assumes clinical operations leadership

## Summary
- Julie VanOrsdel Daves resigns as SVP, Clinical Development Operations effective April 18, 2024 for personal reasons.
- Rebekah de Vitry Fries, current VP of Clinical Operations, will assume leadership of clinical operations.
- De Vitry Fries joined DiaMedica as a consultant on Jan 3, 2024 and became full-time employee on Feb 20, 2024.
- She previously served as Head of Clinical Operations at Epygenix Therapeutics, reporting to same CMO Lorianne Musuoka.

## SEC filing metadata
- accession: 0001437749-24-011645
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2024-04-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774924011645/0001437749-24-011645-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774924011645/dmtp20240408_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-011645
- JSON: https://secwatch.observer/filing/0001437749-24-011645.json
- Plain text: https://secwatch.observer/filing/0001437749-24-011645.txt

## Key facts
- Executive change
  Julie VanOrsdel Daves resigned as Senior Vice President, Clinical Development Operations at DiaMedica Therapeutics Inc..
  - Action: resigned
  - Role: Senior Vice President, Clinical Development Operations
  source text: Julie VanOrsdel Daves MSHS, CCRP notified us of her resignation as Senior Vice President, Clinical Development Operations of DiaMedica Therapeutics Inc. (“DiaMedica”), effective as of April 18, 2024, for personal reasons.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401040/000143774924011645/0001437749-24-011645-index.htm
- Executive change
  Rebekah de Vitry Fries changed role as other_named_officer at DiaMedica Therapeutics Inc..
  - Action: assumed leadership of clinical operations
  source text: Following the departure of Ms. Daves, Rebekah de Vitry Fries, who currently serves as DiaMedica’s Vice President of Clinical Operations, will assume leadership of DiaMedica’s clinical operations.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401040/000143774924011645/0001437749-24-011645-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.